• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

c-erbB-2蛋白的转化潜能受其羧基末端结构域自磷酸化的调控。

The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.

作者信息

Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T

机构信息

Department of Oncogene Research, Osaka University, Japan.

出版信息

Mol Cell Biol. 1991 Feb;11(2):833-42. doi: 10.1128/mcb.11.2.833-842.1991.

DOI:10.1128/mcb.11.2.833-842.1991
PMID:1671296
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC359735/
Abstract

The mutant c-erbB-2 protein with Glu instead of Val-659 exhibited transforming activity in NIH 3T3 cells. This protein showed enhanced tyrosine kinase activity in vitro and enhanced autophosphorylation at Tyr-1248 located proximal to the carboxyl terminus. Enhanced tyrosine phosphorylation of several cellular proteins was detected in cells expressing the Glu-659 c-erbB-2 protein. Introduction of an additional mutation at the ATP-binding site (Lys-753 to Met) of this protein resulted in abolition of its transforming ability. These data indicate that the transforming potential of c-erbB-2 is closely correlated with elevated tyrosine kinase activity of the gene product. To investigate the role of autophosphorylation in cell transformation, we introduced an additional mutation at the autophosphorylation site of the Glu-659 c-erbB-2 protein (Tyr-1248 to Phe). This mutant protein exhibited lower tyrosine kinase activity and lower transforming activity. On the other hand, when the carboxyl-terminal 230 amino acid residues were deleted from the c-erbB-2 protein, the tyrosine kinase activity and cell-transforming activity of the protein were enhanced. Thus, the carboxyl-terminal domain, which contains the major autophosphorylation site, Tyr-1248, may regulate cellular transformation negatively and autophosphorylation may eliminate this negative regulation.

摘要

具有谷氨酸而非缬氨酸-659的突变型c-erbB-2蛋白在NIH 3T3细胞中表现出转化活性。该蛋白在体外显示出增强的酪氨酸激酶活性,并且在靠近羧基末端的Tyr-1248处的自身磷酸化增强。在表达谷氨酸-659 c-erbB-2蛋白的细胞中检测到几种细胞蛋白的酪氨酸磷酸化增强。在该蛋白的ATP结合位点(赖氨酸-753突变为甲硫氨酸)引入额外突变导致其转化能力丧失。这些数据表明,c-erbB-2的转化潜力与该基因产物升高的酪氨酸激酶活性密切相关。为了研究自身磷酸化在细胞转化中的作用,我们在谷氨酸-659 c-erbB-2蛋白的自身磷酸化位点(Tyr-1248突变为苯丙氨酸)引入了额外突变。这种突变蛋白表现出较低的酪氨酸激酶活性和较低的转化活性。另一方面,当从c-erbB-2蛋白中缺失羧基末端230个氨基酸残基时,该蛋白的酪氨酸激酶活性和细胞转化活性增强。因此,包含主要自身磷酸化位点Tyr-1248的羧基末端结构域可能对细胞转化起负调节作用,而自身磷酸化可能消除这种负调节。

相似文献

1
The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain.c-erbB-2蛋白的转化潜能受其羧基末端结构域自磷酸化的调控。
Mol Cell Biol. 1991 Feb;11(2):833-42. doi: 10.1128/mcb.11.2.833-842.1991.
2
The role of autophosphorylation in modulation of erbB-2 transforming function.
New Biol. 1990 Feb;2(2):187-95.
3
Carboxyl-terminal deletion and point mutations decrease the transforming potential of the activated rat neu oncogene product.
Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7335-9. doi: 10.1073/pnas.89.16.7335.
4
Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential.表皮生长因子受体介导的组织特异性转化:erbB 产物的 ATP 结合口袋内的单个点突变增加其内在激酶活性并激活其肉瘤发生潜能。
Proc Natl Acad Sci U S A. 1990 Dec;87(23):9103-7. doi: 10.1073/pnas.87.23.9103.
5
Biochemical comparisons of the normal and oncogenic forms of insect cell-expressed neu tyrosine kinases.昆虫细胞表达的neu酪氨酸激酶正常形式与致癌形式的生化比较。
J Biol Chem. 1992 Jul 15;267(20):13851-6.
6
Structural elements that regulate pp59c-fyn catalytic activity, transforming potential, and ability to associate with polyomavirus middle-T antigen.调节pp59c-fyn催化活性、转化潜能以及与多瘤病毒中T抗原结合能力的结构元件。
J Virol. 1991 Jan;65(1):170-9. doi: 10.1128/JVI.65.1.170-179.1991.
7
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma.Ret/ptc2的完整致癌活性取决于酪氨酸539,它是磷脂酶Cγ的一个对接位点。
Mol Cell Biol. 1996 May;16(5):2151-63. doi: 10.1128/MCB.16.5.2151.
8
Protein tyrosine kinase activities of the epidermal growth factor receptor and ErbB proteins: correlation of oncogenic activation with altered kinetics.表皮生长因子受体和ErbB蛋白的蛋白酪氨酸激酶活性:致癌激活与动力学改变的相关性
Mol Cell Biol. 1992 May;12(5):2010-6. doi: 10.1128/mcb.12.5.2010-2016.1992.
9
The multiple endocrine neoplasia type 2B point mutation alters long-term regulation and enhances the transforming capacity of the epidermal growth factor receptor.2B型多发性内分泌腺瘤病的点突变改变了长期调节并增强了表皮生长因子受体的转化能力。
J Biol Chem. 1996 Mar 8;271(10):5850-8. doi: 10.1074/jbc.271.10.5850.
10
Disease tropism of c-erbB: effects of carboxyl-terminal tyrosine and internal mutations on tissue-specific transformation.c-erbB的疾病嗜性:羧基末端酪氨酸和内部突变对组织特异性转化的影响。
Proc Natl Acad Sci U S A. 1989 Sep;86(18):7164-8. doi: 10.1073/pnas.86.18.7164.

引用本文的文献

1
An Unbiased Functional Genetics Screen Identifies Rare Activating ERBB4 Mutations.一项无偏功能性遗传学筛选鉴定出罕见的激活型 ERBB4 突变。
Cancer Res Commun. 2022 Jan 7;2(1):10-27. doi: 10.1158/2767-9764.CRC-21-0021. eCollection 2022 Jan.
2
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.截短型 FGFR2 是多种癌症中具有临床可操作性的致癌基因。
Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10.
3
HER2-mediated enhancement of Ebola virus entry.HER2 介导增强埃博拉病毒进入。

本文引用的文献

1
Epidermal growth factor stimulates the phosphorylation of synthetic tyrosine-containing peptides by A431 cell membranes.
Proc Natl Acad Sci U S A. 1982 Mar;79(5):1443-7. doi: 10.1073/pnas.79.5.1443.
2
Autophosphorylation sites on the epidermal growth factor receptor.表皮生长因子受体上的自磷酸化位点。
Nature. 1984;311(5985):483-5. doi: 10.1038/311483a0.
3
The neu oncogene encodes an epidermal growth factor receptor-related protein.神经癌基因编码一种与表皮生长因子受体相关的蛋白质。
PLoS Pathog. 2020 Oct 14;16(10):e1008900. doi: 10.1371/journal.ppat.1008900. eCollection 2020 Oct.
4
Microscaled proteogenomic methods for precision oncology.微尺度蛋白质基因组学方法在精准肿瘤学中的应用。
Nat Commun. 2020 Jan 27;11(1):532. doi: 10.1038/s41467-020-14381-2.
5
Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer.HER2 靶向治疗的进展:超越乳腺癌和胃癌的新型药物和机会。
Clin Cancer Res. 2019 Apr 1;25(7):2033-2041. doi: 10.1158/1078-0432.CCR-18-2275. Epub 2018 Nov 15.
6
Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3.针对结直肠癌中的 HER2:ERBB2 和 ERBB3 扩增和短变异突变的全景。
Cancer. 2018 Apr 1;124(7):1358-1373. doi: 10.1002/cncr.31125. Epub 2018 Jan 16.
7
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells.在乳腺癌细胞中,曲妥珠单抗治疗后,协同但不同的早期共信号事件源自ERBB2和ERBB1受体。
Oncotarget. 2017 May 8;8(36):60109-60122. doi: 10.18632/oncotarget.17686. eCollection 2017 Sep 1.
8
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.通过HER2-ERK1/2通路的异常信号传导可预测早期非小细胞肺癌(NSCLC)患者无病生存期和总生存期的缩短。
J Cancer. 2017 Jan 15;8(2):227-239. doi: 10.7150/jca.17093. eCollection 2017.
9
Mechanisms of tumor cell resistance to the current targeted-therapy agents.肿瘤细胞对当前靶向治疗药物的耐药机制。
Tumour Biol. 2016 Aug;37(8):10021-39. doi: 10.1007/s13277-016-5059-1. Epub 2016 May 7.
10
A genetic basis for the variation in the vulnerability of cancer to DNA damage.癌症对 DNA 损伤易感性的遗传基础。
Nat Commun. 2016 Apr 25;7:11428. doi: 10.1038/ncomms11428.
Nature. 1986;319(6050):226-30. doi: 10.1038/319226a0.
4
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.人类乳腺癌:HER-2/neu癌基因扩增与复发及生存的相关性。
Science. 1987 Jan 9;235(4785):177-82. doi: 10.1126/science.3798106.
5
Substrate specificities of tyrosine-specific protein kinases toward cytoskeletal proteins in vitro.
J Biol Chem. 1986 Nov 5;261(31):14797-803.
6
Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor.表皮生长因子(EGF)受体即时及延迟作用中对内在蛋白酪氨酸激酶的需求
Nature. 1987;328(6133):820-3. doi: 10.1038/328820a0.
7
Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation.通过其酪氨酸自身磷酸化的主要羧基末端位点突变改变表皮生长因子受体活性。
J Biol Chem. 1988 Mar 15;263(8):3610-7.
8
Stage- and tissue-specific expression of the neu oncogene in rat development.神经癌基因在大鼠发育过程中的阶段和组织特异性表达。
Proc Natl Acad Sci U S A. 1987 Dec;84(23):8498-501. doi: 10.1073/pnas.84.23.8498.
9
Subversion of growth regulatory pathways in malignant transformation.
Biochim Biophys Acta. 1987 Nov 25;907(3):219-44. doi: 10.1016/0304-419x(87)90007-2.
10
Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue.c-erbB-2癌基因的基因改变在胃管状腺癌中频繁发生,且常伴有v-erbA同源物的扩增。
Oncogene. 1988 Mar;2(3):283-7.